Resveratrol post-treatment protects against neonatal brain injury after hypoxia-ischemia.
Neonatal hypoxic-ischemic brain injury is a devastating disease with limited treatment options. Preventive treatment with resveratrol has indicated to be well tolerated and has lower toxicity in both experimental models and human patients. However, whether resveratrol administration post-hypoxic-ischemic protects against neonatal hypoxic-ischemic injury is not known. Here we reported that post-treatment with resveratrol significantly reduced brain damage at 7-day after the injury. We found that resveratrol reduced the expression levels of key inflammatory factors at the mRNA and protein levels, and at least partially via inhibiting microglia activation. Moreover, resveratrol exerted an anti-apoptotic effect, as assessed by TUNEL staining, and altered the expression of the apoptosis-related genes Bax, Bcl-2 and caspase3. Our data indicate that post-treatment with resveratrol protects against neonatal hypoxic-ischemic brain injury and suggest a promising therapeutic strategy to this disease.
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Shulin
S
Pan
The Institute of Life Sciences, Wenzhou University, Wenzhou 325035, China.
Songlin
S
Li
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Yingying
Y
Hu
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Hao
H
Zhang
The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
Yanlong
Y
Liu
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Huai
H
Jiang
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Mingchu
M
Fang
The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
Zhengmao
Z
Li
The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
Kebin
K
Xu
The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
Hongyu
H
Zhang
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Zhenlang
Z
Lin
The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China.
Jian
J
Xiao
D000818:Animals; D000831:Animals, Newborn; D001930:Brain Injuries / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D053148:Caspase 3 / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects; D020925:Hypoxia-Ischemia, Brain / Q000150:complications* / Q000276:immunology / Q000473:pathology; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D051381:Rats; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000494:pharmacology; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
C494828:Bax protein, rat; C000617196:Bcl2 protein, rat; D016207:Cytokines; D018696:Neuroprotective Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D013267:Stilbenes; D051028:bcl-2-Associated X Protein; C505410:Casp3 protein, rat; D053148:Caspase 3; D000077185:Resveratrol
apoptosis; brain damage; hypoxia-ischemia; inflammation; resveratrol